First-year costs of treating prostate cancer: estimates from SEER-Medicare data (Q33452520)

26 July 2017

title

First-year costs of treating prostate cancer: estimates from SEER-Medicare data (English)

1 reference

26 July 2017

1 reference

C G Roehrborn

1

1 reference

26 July 2017

P Albertsen

2

1 reference

26 July 2017

M E Stokes

3

1 reference

26 July 2017

L Black

4

1 reference

26 July 2017

A Benedict

5

1 reference

26 July 2017

publication date

26 May 2009

1 reference

Prostate Cancer and Prostatic Diseases

26 July 2017

published in

1 reference

26 July 2017

volume

12

1 reference

26 July 2017

issue

4

1 reference

26 July 2017

page(s)

355-360

1 reference

https://scigraph.springernature.com/pub.10.1038/pcan.2009.21

26 July 2017

exact match

0 references

cites work

Assessing quality using administrative data

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.21

The influence of finasteride on the development of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.21

Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.21

Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.21

Estimating rates of true high-grade disease in the prostate cancer prevention trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.21

High-grade prostate cancer and the prostate cancer prevention trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.21

Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.21

Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.21

Predictors of Medicare costs in elderly beneficiaries with breast, colorectal, lung, or prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.21

Relationship of first-year costs of treating localized prostate cancer to initial choice of therapy and stage at diagnosis: results from the CAPSURE database

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.21

Evaluation of trends in the cost of initial cancer treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.21

Trends in treatment costs for localized prostate cancer: the healthy screenee effect.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.21

Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.21

Epidemiological trends and financial outcomes in radical prostatectomy among Medicare beneficiaries, 1991 to 1993.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.21

Utilization and outcomes of minimally invasive radical prostatectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.21

31 March 2020

Identifiers

DOI

10.1038/PCAN.2009.21

1 reference

26 July 2017

1 reference